Why Karyopharm Shares Are Plunging
- Karyopharm Therapeutics Inc (Get Free Alerts for KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities."
- While CEO Paulson looks for Shah's replacement, he has recruited two Big Pharma vets to take up key posts on the team:
- Patricia Judson, who led women's oncology at GlaxoSmithKline and AstraZeneca, will become the SVP of medical strategy.
- From AbbVie, Amgen, and Eli Lilly, Stuart Poulton has been appointed SVP of strategy and portfolio management.
- Karyopharm unveiled Phase 3 results for Xpovio in endometrial cancer, noting the drug cut the risk of disease progression or death by 30% compared to placebo, with median progression-free survival coming in at 5.7 months for the active arm and 3.8 months for the placebo cohort.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.